GeneDx Holdings Corp. Class A Common Stock (WGS)
Stock · NASDAQ · Health Care
$63.75as of 10/16/2026
Price chart
Active signals
WGS Signal Track Record
How signals performed across all stocks →What WGS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -2.5% | 42% | September 29, 2026 |
| Bollinger Band Breakout | 22 | -0.2% | 50% | September 15, 2026 |
| Bollinger Band Breakdown | 20 | +1.4% | 50% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +12.3% | 60% | September 10, 2026 |
| Any 20-session window (baseline) | +1.9% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx H…
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- Employees
- 1,300
- Website
- sema4.com/
Fundamentals
- 1-day range
- $62.49$70.19
- Market cap
- $2.08B
- P/E (trailing)
- —
- P/E (forward)
- 53.07
- EPS (trailing)
- $-3.63
- Dividend yield
- —
- Beta
- 2.02
- Avg. volume
- 724.9K
How GeneDx Holdings Corp. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
GeneDx Holdings Corp. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- WGSGeneDx Holdings Corp. Class A Common Stock$63.61▼ 9.41%Market cap $2.08BP/E —$32.21$170.87
- AVAHAveanna Healthcare Holdings Inc. Common Stock$12.34▼ 2.37%Market cap $2.03BP/E 10.04$5.93$14.71
- ADUSAddus HomeCare Corporation Common Stock$115.98▼ 0.44%Market cap $2.22BP/E 20.70$87.95$124.44
- INNVInnovAge Holding Corp. Common Stock$8.85▼ 1.45%Market cap $1.49BP/E —$3.94$12.64
- PRVAPrivia Health Group Inc. Common Stock$22.52▼ 0.44%Market cap $2.77BP/E 102.74$18.92$28.82
- PNTGThe Pennant Group Inc. Common Stock$41.87▼ 0.95%Market cap $1.36BP/E 46.02$22.26$42.74
- TDOCTeladoc Health Inc. Common Stock$5.67▼ 5.03%Market cap $1.21BP/E —$4.4$9.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| WGS GeneDx Holdings Corp. Class A Common Stock | $2.08B | — | $63.61 | ▼ 9.41% | $32.21$170.87 |
| AVAH Aveanna Healthcare Holdings Inc. Common Stock | $2.03B | 10.04 | $12.34 | ▼ 2.37% | $5.93$14.71 |
| ADUS Addus HomeCare Corporation Common Stock | $2.22B | 20.70 | $115.98 | ▼ 0.44% | $87.95$124.44 |
| INNV InnovAge Holding Corp. Common Stock | $1.49B | — | $8.85 | ▼ 1.45% | $3.94$12.64 |
| PRVA Privia Health Group Inc. Common Stock | $2.77B | 102.74 | $22.52 | ▼ 0.44% | $18.92$28.82 |
| PNTG The Pennant Group Inc. Common Stock | $1.36B | 46.02 | $41.87 | ▼ 0.95% | $22.26$42.74 |
| TDOC Teladoc Health Inc. Common Stock | $1.21B | — | $5.67 | ▼ 5.03% | $4.4$9.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Top 3 Healthcare Stocks To Watch In October 2026Yahoo · 10/10/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 10/9/2026
- Teladoc Strengthens Solo Platform With New AI-Powered Care ToolsYahoo · 10/8/2026
- Encompass Health Expands Rehab Footprint With New Maine HospitalYahoo · 10/7/2026
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026Yahoo · 10/7/2026
- GeneDx To Present New Results At International Consortium On Newborn Sequencing For Its Genomic Newborn ScreeningBenzinga · 10/7/2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric CareYahoo · 10/2/2026
- Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83Benzinga · 10/1/2026
Insider Activity
Insider Actions →- Fuchs Thomas · September 17, 2026 · Option Exercise1.1K
- Kevin Feeley · September 16, 2026 · Option Exercise7.2K
- Kevin Feeley · September 16, 2026 · Sale1.1K @ $99
- Kevin Feeley · September 16, 2026 · Sale1.5K @ $98.27
- Katherine Stueland · September 16, 2026 · Sale3.0K @ $99
- Katherine Stueland · September 16, 2026 · Sale4.1K @ $98.27
- Kevin Feeley · September 16, 2026 · Sale541 @ $96.9
- Kevin Feeley · September 16, 2026 · Sale52 @ $95.41
- Kevin Feeley · September 16, 2026 · Sale586 @ $94.26
- Katherine Stueland · September 16, 2026 · Option Exercise18.8K
- Katherine Stueland · September 16, 2026 · Sale1.5K @ $96.9
- Katherine Stueland · September 16, 2026 · Sale148 @ $95.41
- Katherine Stueland · September 16, 2026 · Sale1.6K @ $94.26
- Katherine Stueland · September 9, 2026 · Sale3.7K @ $84.22
- Kevin Feeley · September 9, 2026 · Option Exercise2.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 31.47M
- Total value held
- $2.00B
- Institutional holders
- 237
- Unknown3.23M
- Unknown3.01M
- Unknown1.55M
- Unknown1.37M
- Unknown1.33M
- Unknown1.32M
- Unknown858.6K
- Unknown775.3K
- Unknown768.0K
- Unknown689.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data
GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.